HIV drug linked to deadly skin condition
Tibotec Therapeutics, makers of prescription medication Intelence (etravirine) used to control HIV infection in adults, recently notified health care professionals that the medication has been linked to a rare but life-threatening skin condition known as Stevens Johnson Syndrome, SJS.
Early this year, Intelence was approved by the the Food and Drug Administration (FDA) for use in the treatment of HIV. At that time, data indicated a slight risk of SJS.
SJS, and its most severe form, toxic epidermal necrolysis, TEN, are identified by a rash on the skin that blisters over causing the skin to peel off in sheets. The condition is extremely painful and often requires hospitalization to treat the open wounds on the skin, mouth, eyes and other mucous membranes. Complications include infection, dehydration, vision problems, organ dysfunction and death.
